Item 5. Other Information
ITEM 5 - OTHER INFORMATION
None.
78
Table of Contents
ITEM 6 - EXHIBITS
Incorporated by Reference
Exhibit
Number Exhibit Description Form File No. Date of
First
Filing Exhibit
Number Provided
Herewith
10.01*
Amendment Number Nine to Non-Exclusive Wholesale Distribution Agreement, dated February 1, 2023, by and between DexCom, Inc. and RGH Enterprises, LLC.
— — — — X
10.02*
Amendment Number Ten to Non-Exclusive Distribution Agreement, dated February 1, 2023, by and between DexCom, Inc. and RGH Enterprises, LLC.
— — — — X
10.03*
Amendment Number Twelve to Amended and Restated Non-Exclusive Distribution Agreement, dated February 1, 2023, by and between DexCom, Inc. and Byram Healthcare.
— — — — X
31.01
Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a).
— — — — X
31.02
Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a).
— — — — X
32.01**
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b).
— — — — X
32.02**
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b).
— — — — X
101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document X
101.SCH Inline XBRL Taxonomy Extension Schema Document X
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document X
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document X
79
Table of Contents
Incorporated by Reference
Exhibit
Number Exhibit Description Form File No. Date of
First
Filing Exhibit
Number Provided
Herewith
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document X
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document X
104 Cover Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 is formatted in Inline XBRL
X
* Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
** This certification is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that Dexcom specifically incorporates it by reference.
80
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DEXCOM, INC.
(Registrant)
Dated: April 27, 2023 By: /s/ KEVIN R. SAYER
Kevin R. Sayer,
Chairman of the Board of Directors,
President and Chief Executive Officer
(Principal Executive Officer)
Dated: April 27, 2023 By: /s/ JEREME M. SYLVAIN
Jereme M. Sylvain,
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)
81
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.